BiotechTube
SpectraWAVE

SpectraWAVE

Cambridge, United States· Est.
spectrawave.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $70M

Overview

SpectraWAVE is a private, commercial-stage medical device company based in Cambridge, Massachusetts, focused on transforming coronary care. The company's integrated HyperVue platform merges high-definition intravascular imaging (DeepOCT+NIRS) with an AI-enabled, wire-free fractional flow reserve (FFR) measurement tool (X1-FFR), designed to streamline workflow in the catheterization lab. With 50+ employees and a vertically integrated operation in Bedford, MA, SpectraWAVE targets the significant global market for coronary artery disease by providing a unified solution for anatomical and physiological assessment. The company received 510(k) clearance for its X1-FFR technology in October 2025, marking a key regulatory milestone.

CardiovascularCoronary Artery Disease

Technology Platform

Integrated intravascular imaging and physiology platform combining DeepOCT+NIRS for high-resolution plaque characterization with AI-enabled, wire-free FFR (X1-FFR) derived from a single angiogram.

Funding History

3
Total raised:$70M
Series B$40M
Series A$25M
Seed$5M

Opportunities

The convergence of the large intravascular imaging and physiology guidance markets presents a major opportunity for an integrated platform that simplifies cath lab workflow.
Growing clinical emphasis on personalized, optimized PCI and the global burden of CAD drive demand for advanced tools.
The recent FDA clearance for X1-FFR is a key catalyst for commercial growth.

Risk Factors

Faces intense competition from large, established MedTech companies with deep sales channels and entrenched products.
Commercial success depends on convincing hospitals to adopt a new platform over single-modality standards.
Must continuously demonstrate the clinical and economic superiority of its AI-driven, wire-free FFR against the traditional wire-based method.

Competitive Landscape

Competes directly with major players like Abbott (OCT, IVUS, Pressure Wires), Philips (IVUS), and Boston Scientific (IVUS) in the intravascular imaging and physiology markets. Differentiation hinges on being the only platform to combine high-definition OCT+NIRS imaging with a wire-free, drug-free FFR solution on a single system, targeting workflow efficiency as a key competitive advantage.

More companies in United States →